key: cord-0762307-ld8481fj authors: Hoang, Tung; Nguyen, Trung Quang; Tran, Tho Thi Anh title: Genetic Susceptibility of ACE2 and TMPRSS2 in Six Common Cancers and Possible Impacts on COVID-19 date: 2020-12-29 journal: Cancer Res Treat DOI: 10.4143/crt.2020.950 sha: 42fd02f46bb41a9cf8b2faa09c2319e22e0a7f33 doc_id: 762307 cord_uid: ld8481fj PURPOSE: Coronavirus disease 2019 (COVID-19) pandemic has spread worldwide rapidly and patients with cancer have been considered as a vulnerable group for this infection. This study aimed to examine the expressions of angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2) in tumor tissues of six common cancer types. MATERIALS AND METHODS: The expression levels of ACE2 and TMPRSS2 in tumors and control samples were obtained from online databases. Survival prognosis and biological functions of these genes were investigated for each tumor type. RESULTS: There was the overexpression of ACE2 in colon and stomach adenocarcinomas compared to controls, meanwhile colon and prostate adenocarcinomas showed a significantly higher expression of TMPRSS2. Additionally, survival prognosis analysis has demonstrated that upregulation of ACE2 in liver hepatocellular carcinoma was associated with higher overall survival (hazard ratio, 0.65; p=0.016) and disease-free survival (hazard ratio, 0.66; p=0.007), while overexpression of TMPRSS2 was associated with a 26% reduced risk of death in lung adenocarcinoma (p=0.047) but 50% increased risk of death in breast invasive carcinoma (p=0.015). CONCLUSION: There is a need to take extra precautions for COVID-19 in patients with colorectal cancer, stomach cancer, and lung cancer. Further information on other types of cancer at different stages should be investigated. The expression levels of ACE2 and TMPRSS2 in tumors and control samples were obtained from the Gene Expression Profiling Interactive Analysis 2 (GEPIA2) database using RNA sequencing data from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) [15] . The cutoff criterion was set at adjusted p-value < 0.01 and log2 fold change > 1 or < -1. Expression levels of ACE2 and RMPSS2 in lung adenocarcinoma (LUAD), breast invasive carcinoma (BRCA), colon adenocarcinoma (COAD), prostate adenocarcinoma (PRAD), stomach adenocarcinoma (STAD), and liver hepatocellular carcinoma (LIHC) and their subtypes (except STAD due to data unavailability) were compared with normal samples using a two-sample t test and an analysis of variance (ANOVA). Expression of ACE2 and TMPRSS2 in the prognosis of six cancer types was examined utilizing the GEPIA2 database [15] . Median values of gene expression were selected as cutoff points in the prognostic analysis of overall survival (OS) and disease-free survival (DFS). Kaplan-Meier plot for the probability of survival throughout time, hazard ratio (HR) by a Cox proportional hazard model, and p-value by logrank test for the OS and DFS between high and low expression groups was reported. The list of 100 most co-expressed genes with ACE2 (S1 Table) and TMPRSS2 (S2 Table) in each tumor was obtained from the GEPIA2 database [15] . Then, Kyoto Encyclopedia of Genes and Genomes (KEGG) 2019 Human biological functions of ACE2 and TMPRSS2 were explored by applying the pathway enrichment analysis in the EnRichr database. p-values were selected at 0.05 for the cutoff [16] . Data from the GEPIA2 database revealed that mRNA levels of ACE2 expression were significantly higher in COAD and STAD, whereas mRNA levels of TMPRSS2 expression were significantly lower in BRCA, but higher in COAD and PRAD, compared with the control group (Fig. 1) . Analysis of subtype tumors from the GENT2 database also showed the significantly higher ACE2 expression of COAD subtypes including microsatellite instability-high (MSI-H), microsatellite instability-low (MSI-L), and microsatellite stable (MSS), in comparison with the control group (S3 Fig.) . However, data on STAD subtypes were not available. In terms of TMPRSS2 expression, significantly lower mRNA levels were only observed for luminal A and luminal B subtypes of BRCA, but not for basal-like and human epidermal growth factor receptor 2 subtypes, compared with the control group (S4 Fig.) . Significantly higher TMPRSS2 was also observed for i-Cluster 1 and i-Cluster 3, but not for i-Cluster 2 subtypes of PRAD, compared with the control group. Proximal inflammatory and proximal proliferative subtypes of LUAD additionally expressed lower mRNA levels of TMPRSS2 than the control group, but a significant association was not observed for the terminal respiratory unit subtype. The Kaplan-Meier plots for the effect of ACE2 and TM-PRSS2 expression on OS and DFS in different tumor types are presented in S5-S8 Fig. and summarized in Table 1 . Overall, higher levels of ACE2 in LIHC were associated with higher OS (HR, 0.65; p=0.016) and DFS (HR, 0.66; p=0.007). Additionally, higher levels of TMPRSS2 were associated with a 26% reduced risk of death in LUAD (p=0.047) but a 50% increased risk of death in BRCA (p=0.015). On the one hand, the result of the KEGG pathway enrichment analysis for ACE2 and their top 100 co-expressed genes is presented in Fig. 2 and S9 Table. The most significant pathways in LUAD, BRCA, COAD, PRAD, STAD, and LIHC were phenylalanine metabolism (p=0.003), tryptophan metabolism (p=0.001), vitamin digestion and absorption (p < 0.001), steroid hormone biosynthesis (p=0.003), fat digestion and absorption (p=0.001), and renin-angiotensin system (p=0.006). On the other hand, the result of the KEGG pathway enrichment analysis for TMPRSS2 and their top 100 co-expressed genes is presented in Fig. 3 and S10 Table. The LIHC were starch and sucrose metabolism (p=0.014), proximal tubule bicarbonate reclamation (p=0.006), glycosphingolipid biosynthesis (p=0.022), beta-Alanine metabolism (p=0.001), glycerophospholipid metabolism (p=0.004), and prostate cancer (p=0.001). Melanoma ue during the pandemic, it is essential to determine which type of cancer will be at a high risk of getting severity condition with COVID-19 infection. Since SAR-CoV-2 employs ACE2 and TMPRSS2 for entering host cells and priming [8] , we evaluated the expression of these genes that might be responsible for the severity of COVID-19 condition in patients with different types of cancer. Our data showed the high expression of ACE2 and TMPRSS2 in COAD and STAD. For COAD, the coincidental result was confirmed at all subtypes regarding microsatellite status including MSI-H, MSI-L, and MSS. A similar finding has been reported in a study from the New York hospital system, which indicated that gastrointestinal cancer appeared to have a higher fatality rate than any type of solid tumor except lung cancer [19] . These might confirm the susceptibility of colorectal cancer and stomach patients to COVID-19 infection. Besides, at the mRNA level, we found that TMPRSS2 expressions were significantly lower in BRCA, but higher in COAD and PRAD, compared with control groups. Notably, it has been proved that TMPRSS2 was upregulated in prostate cancer under androgen stimulation [20] . Thus, it might suggest the risk of PRAD patients and possibly explain the higher proportion of infection prevalence of COVID-19 in males. Interestingly, for lung cancer, we did not see any overexpression of ACE2 but confirmed a significantly lower expression of TMPRSS2 in proximal inflammatory and proximal proliferative subtypes of LUAD than the control group. While it might be beneficial to have low ACE2 receptors for the entry of SARS-CoV-2, ACE2 has been proved to be responsible for anti-inflammatory, thus it might be considered as a protective factor during the infection process. Consequently, the downregulation of ACE2 in lung cancer patients might cause critical conditions by unstoppable inflammation. Given the fact that lung cancer patients account for a major proportion among cancer patients with COV-ID-19, further investigations to clarify specific mechanisms in lung cancer should be performed. We then evaluated the association between the expressions of ACE2 and TMPRSS2 with the prognosis of six types of cancer. We noticed the overexpression of ACE2 in LIHC were associated with higher OS (HR, 0.65; p=0.016) and DFS (HR, 0.66; p=0.007), and upregulation of TMPRSS2 was asso-ciated with 26% reduced risk of mortality in LUAD (p=0.047) but 50% increased risk of death in BRCA (p=0.015). These expression statuses, however, have no correlation with OS and DFS in COAD, STAD, and PRAD. In return, there will be a need to assess the role of these genes in prognosis for COVID-19 patients with cancer. By tracking the biological function of ACE2, TMPRSS2, and 100 similar genes, we can determine the top 10 pathways in six types of cancer. As the immune response is mainly driven in COVID-19 progression [21] , we aimed to find the overlapping pathway which might contribute to the unfavorable prognosis in cancer with COVID-19. Nevertheless, no pathway has been considered a potential key. Approaches to extra center genes and pathways might lead to better findings. In conclusion, our findings suggest the need for priority precautions for colorectal cancer, stomach cancer, and lung cancer during the COVID-19 pandemic. However, the risk of delaying appropriate treatment for cancer might be much greater than the risk of being exposed to COVID-19. Therefore, tailored cancer care with effective health delivery systems is crucial to bring final benefit for oncology patients. Further research on various cancer types/subtypes and cancer stages should be analyzed. Interim guidelines on antiviral therapy for COVID-19 Recovery Collaborative Group Dexamethasone in hospitalized patients with COVID-19: preliminary report piratory syndrome, Middle East respiratory syndrome, and coronavirus disease 2019: a review of clinical evidence COVID-19 vaccines: no time for complacency Comparison of comorbidities in relation to critical conditions among COVID-19 patients: a network meta-analysis Potential role of ACE2 in coronavirus disease 2019 (COVID-19) prevention and management COVID-19 and individual genetic susceptibility/ receptivity: role of ACE1/ACE2 genes, immunity, inflammation and coagulation: might the double X-chromosome in females be protective against SARS-CoV-2 compared to the single X-chromosome in males? SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries Prediction of cancer incidence and mortality in Korea Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2016 Prediction of cancer incidence and mortality in Korea Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2017 Prediction of cancer incidence and mortality in Korea GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis Enrichr: a comprehensive gene set enrichment analysis web server 2016 update Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study Case fatality rate of cancer patients with COVID-19 in a New York hospital system Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2 A dynamic immune response shapes COVID-19 progression